Company news
CNS Pharmaceuticals, Inc. news in 2023
CNS Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
December 17, 2023
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
November 21, 2023
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
November 15, 2023
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
November 14, 2023
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
October 18, 2023
CNS Pharmaceuticals' (NASDAQ: CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
October 10, 2023
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
September 6, 2023
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
August 13, 2023
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
August 13, 2023
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
August 2, 2023
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
August 2, 2023
CNS Pharmaceuticals (NASDAQ: CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
July 26, 2023
CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series
July 4, 2023
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 13, 2023
CNS Pharmaceuticals (NASDAQ: CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
May 24, 2023
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 14, 2023
Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
May 7, 2023
CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC
May 2, 2023
CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
April 26, 2023
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
April 9, 2023
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
April 5, 2023
CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
April 2, 2023
CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event
March 28, 2023
CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues
March 12, 2023
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
March 8, 2023
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
February 6, 2023
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland
January 11, 2023
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event
January 4, 2023
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors
January 2, 2023